Highlights VBI Vaccines Inc. Toronto S.E.

Equities

VBV

CA91822J1030

Delayed Toronto S.E. Other stock markets 05:39:59 2018-03-23 pm EDT			5-day change	1st Jan Change
4.82 ^CAD	-5.12%		-7.66%	-10.58%

May. 15	VBI Vaccines Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 15	Earnings Flash (VBIV) VBI VACCINES Reports Q1 Revenue $1.2M	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

VBI Vaccines Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Earnings Flash (VBIV) VBI VACCINES Reports Q1 Revenue $1.2M	May. 15	MT
VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma	Apr. 03	CI
VBI Vaccines Inc. Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA- Launched eVLP Vaccine Platform	Apr. 02	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 11	DJ
VBI Vaccines Inc. Enter into New License Agreement with Brii Biosciences	Feb. 14	CI
VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting	Nov. 20	CI
Earnings Flash (VBIV) VBI VACCINES Posts Q3 Revenue $6.6M	Nov. 14	MT
VBI Vaccines Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program	23-10-26	CI
VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901	23-09-27	CI
VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM	23-09-07	CI
Earnings Flash (VBIV) VBI VACCINES Reports Q2 Revenue $720,000	23-08-14	MT
VBI Vaccines Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
VBI Vaccines' Hepatitis B Vaccine PreHevbri Is Available in Netherlands, Belgium; Shares Rise Midday	23-07-19	MT
VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults	23-07-19	CI
Brii Biosciences Limited Enters into License Agreements with VBI Vaccines, Inc	23-07-05	CI
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties	23-07-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights VBI Vaccines Inc. Toronto S.E.

Equities

VBV

CA91822J1030

Highlights

Filters